Generate QR code
Open Access
Subscription Access
Semaglutide reduces body weight, but...
https://doi.org/10.36485/1561-6274-2026-30-1-103-111
EDN: EPOLYU
Abstract
Almost half of the world's population suffers from obesity. The prevalence of obesity and excess body weight is steadily increasing. We want to be graceful and slim without making significant efforts. Therefore, new "miraculous" medical drugs for weight loss appear. But their active use, unfortunately, often without a doctor's prescription, can lead to the development of serious consequences. And the more widely the drugs are advertised and used uncontrollably, the more likely the occurrence of adverse reactions. We encountered one of such cases and describe it in the article.
About the Authors
E. V. Kolmakova
North-West State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Associate prof. Elena V. Kolmakova, MD, PhD, Department of Internal Medicine, Nephrology, General and Clinical Pharmacology with a Course in Pharmacy
191015, Saint-Peterburg, Kirochnaea st., 41
Phone: +791811201310
O. A. Vorobieva
National Center for Clinical Morphological Diagnostics
Russian Federation
Russian Federation
Olga A. Vorobyeva MD, PhD, Head of the Department of Kidney Pathology and Difficult Morphological Diagnosis
32 Slavy Avenue, Saint Petersburg 192071
Phone: +7(812)679-42-50
A. N. Isachkina
North-West State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Associate prof. Alina N. Isachkina, MD, PhD, Department of Internal Medicine, Nephrology, General and Clinical Pharmacology with a Course in Pharmacy
191015, Saint-Peterburg, Kirochnaea st., 41
Phone: +79214470948
V. V. Len’kina
North-West State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Victoria V. Len’kina, Department of Internal Medicine, Nephrology, General and Clinical Pharmacology with a Course in Pharmacy, Nephrologist, dialysis department
191015, Saint-Peterburg, Kirochnaea st., 41
Phone: +79817998297
191015, Saint-Peterburg, Kirochnaea st., 41
References
1. Всемирная организация здравоохранения (ВОЗ). Информационный бюллетень. Ожирение и избыточный вес: 2020. URL: https://www.who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight (дата обращения: 26.04.2021)
2. Balanova YuA, Drapkina OM, Kutsenko VA et al. Obesity in the Russian population during the COVID-19 pandemic and associated factors. Data from the ESSERF3 study. Cardiovascular Therapy and Prevention 2023;22(8S):3793. (in Russ.) doi:10.15829/1728-8800-2023-3793. EDN SBUNIG
3. Alferova VI, Mustafina SV. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and metabolism 2022;19(1):96–105. (In Russ.) doi: https://doi.org/10.14341/omet12809
4. Ametov AS, Tsygankova OV. Complex metabolic protection as a modern strategy for the management of type 2 diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie. Endocrinology: News, Opinions, Training 2021;10(2):93–104. (in Russ.) doi: https://doi.org/10.33029/2304-9529-2021-10-2-93-104
5. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 9-й вып. / под ред. ИИ Дедова, МВ Шестаковой, АЮ Майорова. Сахарный диабет 2019;22(S 1):1–212
6. Tsygankova OV, Veretyuk VV, Ametov AS. Incretins today: multiple eff ects and therapeutic potential. Diabetes Mellitus 2019;22(1):70–78. doi: 10.14341/DM9841
7. Gorban VV, Arzumanyan KA, Kostyulina MYu, Mikhaylenko DA et al. Semaglutide: effects on eating behavior. Meditsinskiy Sovet 2024;18(13):115–122. (In Russ.) https://doi.org/10.21518/ms2024-268.
8. Moiz A, Levett JY, Filion KB, Peri K, Reynier P, Eisenberg MJ. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Cardiol 2024 Jul 1;222:121–130. doi: 10.1016/j.amjcard.2024.04.041
9. Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. Journal of the ASEAN Federation of Endocrine Societies 2022;37(2):65–72. https://doi.org/10.15605/jafes.037.02.14
10. Государственный реестр лекарственных средств. Инструкция по применению лекарственного препарата. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=82c8739fd1d5-41dd-aa3d-e22d97462347
11. Shapovalova AB, Smirnov VV, Titova DO. The place of glucagon-like peptide-1 receptor agonists in the drug therapyof obesity at the present stage. Medicine: Theory and Practice. 2024;9(2):40–50. (In Russ.) doi: https://doi.org/10.56871/MTP.2024.47.58.005
12. Регистр лекарственных средств России (РЛС). Семаглутид (Semaglutidum) описание. https://www.rlsnet.ru/active-substance/semaglutid-3921?ysclid=mefisksjn9104446991
13. European Medicines Agency. Byetta; summary of product characteristics. 2018. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Informati-on/human/000698/WC500051845.pdf Accessed 29 May 2018
14. Smirnov AV, Rumyantsev ASh on behalf of the working group. Acute kidney disease. Part I. Nephrology (Saint-Petersburg) 2020;24(1):67–95. (In Russ.) doi:10.36485/1561-6274-2020-24-1-67-95
15. Arefeva AN, Banko VV, Sadovskikh МО, Noskov SМ. Pharmacokinetics of first semaglutid drug in Russian Federation: results of open-label randomized clinical trial. Meditsinskiy Sovet 2023;17(16):77–82. (In Russ.) https://doi.org/10.21518/ms2023-312
Review
For citations:
Kolmakova E.V., Vorobieva O.A., Isachkina A.N., Len’kina V.V. Semaglutide reduces body weight, but... Nephrology (Saint-Petersburg). 2026;30(1):103-111. (In Russ.) https://doi.org/10.36485/1561-6274-2026-30-1-103-111. EDN: EPOLYU
Views:
197
JATS XML
Email this article 